The Gabrail Cancer Center currently has many Clinical Trial opportunities . For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 orĀ via email CSmith@GabrailCancerCenter.com.
A Phase 1/2, Open-Label, Uncontrolled, Multi-Dose Escalation, Cohort Expansion Study to Evaluate the safety, Tolerability, Pharmacokinetics, and Prelimiary Efficacy of ASN002 in Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, and Advanced Solid Tumors
A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients with Advanced Solid Tumors
An Open-Label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refactory Solid Tumors or Hematological Malignancies Who Have Mild, Moderate, and Severe Renal Impairment
An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Return to Clinical Trials at GCC